Table 2 . Allogeneic blood product transfusions.
|
Caproamin Fides
(n=100) |
TXA
(n=100) |
Control
(n=100) |
Caproamin Fides
vs. control |
TXA vs. control |
Caproamin Fides
vs. TXA |
|||||
| Effect size | P | Effect size | P | Effect size | P | |||||
| Transfusions During Operation | PRBCs (pts) | 65 (65) | 70 (70) | 79 (79) |
RR=0.49 (0.26-0.93) |
0.02* |
RR=0.62 (0.32-1.18) |
0.14 | RR=1.25 (0.69-2.27) | 0.45 |
| FFP (pts) | 5 (5) | 7 (7) | 11 (11) |
RR=0.42 (0.14-1.27) |
0.12 |
RR=0.66 (0.22-1.64) |
0.32 | RR=1.43 (0.43-4.66) | 0.55 | |
| Platelets (pts) | 4 (4) | 5 (5) | 6 (6) |
RR=0.65 (0.17-2.38) |
0.51 |
RR=0.82 (0.24-2.79) |
0.75 | RR=1.26 (0.32-4.84) | 0.73 | |
| PRBCs (U) | 1.13±1.09 | 1.30±1.08 | 1.68±1.37 | MD=-0.55 | 0.001* | MD=-0.38 | 0.02* | MD=-0.17 | 0.31 | |
| FFP (U) | 0.22±0.99 | 0.24±0.92 | 0.45±0.99 | MD=-0.23 | 0.14 | MD=-0.21 | 0.18 | MD=-0.02 | 0.89 | |
| Platelets (U) | 0.13±0.79 | 0.19±0.89 | 0.22±0.91 | MD=-0.07 | 0.57 | MD=-0.03 | 0.80 | MD=-0.04 | 0.74 | |
| Transfusions During ICU Stay | PRBCs (pts) | 53 (53) | 60 (60) | 74 (74) |
RR=0.31 (0.17-0.56) |
0.001* |
RR=0.52 (0.28-0.96) |
0.03* |
R=1.69 (0.96-2.96) |
0.06 |
| FFP (pts) | 19 (19) | 23 (23) | 38 (38) |
RR=0.38 (0.20-0.72) |
0.003* |
RR=0.48 (0.26-0.90) |
0.02* |
R=1.27 (0.64-2.52) |
0.48 | |
| Platelets (pts) | 5 (5) | 6 (6) | 8 (8) |
RR=0.60 (0.19-1.91) |
0.39 |
RR=0.73 (0.24-2.19) |
0.58 |
R=1.21 (0.35-4.11) |
0.75 | |
| PRBCs (U) | 0.78±0.08 | 1.25±0.53 | 1.65±0.55 | MD=-0.87 | <0.001* | MD=-0.40 | 0.04* | MD=-0.47 | 0.01* | |
| FFP (U) | 0.57±0.28 | 0.84±0.69 | 1.30±0.92 | MD=-0.73 | 0.002* | MD=-46 | 0.05* | MD=-0.27 | 0.24 | |
| Platelets (U) | 0.22±0.01 | 0.30±0.20 | 0.39±0.15 | MD=-0.17 | 0.33 | MD=-0.09 | 0.61 | 0.08 | 0.65 | |
Data are shown as number (percentage) and mean±standard deviation.
FFP= fresh frozen plasma; MD= mean difference; PRBCs= packed red blood cells; pts= patients; RR= relative risk; U= units.
* Statistically significant.